Kurzfassung

A phase III, randomized, double.blindes study comparing the combination of the BRAF inhibitor dabrafenib and the MEK inhibitor trametinib to dabrafenib and placebo as first-line therapy in subjects with unresectable (Stage IIIC) or metastatic (Stage IV) BRAF V600E/K mutation positive cutaneous melanoma